Fungustatin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fungustatin

What is Fungustatin?

Fungustatin is a pharmaceutical agent categorized as an antifungal medication. It is primarily used to manage and treat infections caused by various types of fungi and yeasts. The active mechanism of the drug involves disrupting the growth or integrity of fungal cells, which helps the body’s natural defenses eliminate the infection.

Therapeutic Purpose

The medication is designed to address specific fungal overgrowths that can affect different parts of the body. It is most commonly associated with the treatment of candidiasis, a condition resulting from the Candida genus of yeast. These infections can occur in various locations, including the skin, mouth, and intestinal tract.

How it Functions

Fungustatin belongs to a class of antifungals that interact with the cell membranes of susceptible fungi. By binding to specific components within the fungal cell wall, the medication creates openings or instabilities that cause the cell's internal contents to leak out. This process effectively halts the reproduction of the fungi or destroys the cells entirely.

Characteristics and Use

As an antifungal treatment, Fungustatin is selective in its action, meaning it targets fungal cells specifically while leaving bacterial populations unaffected. Because it is not an antibiotic, it is not used for the treatment of viral or bacterial infections. Its application is strictly limited to fungal pathogens identified as sensitive to its chemical properties.

What side effects are possible with Fungustatin?

Possible side effects and safety information

The safety profile of Fungustatin (Fluconazole) is characterized by classifying possible adverse reactions based on their frequency, as documented in regulatory sources such as the FDA and EMA.

Official Adverse Reaction Classification

The most frequently listed adverse reactions typically involve the gastrointestinal and nervous systems, alongside transient changes in liver markers.

  • Common Reactions (ge 1/100 to < 1/10): Headache, abdominal pain, diarrhea, nausea, vomiting, rash, and increased levels of liver enzymes (ALT, AST, alkaline phosphatase).
  • Uncommon Reactions (ge 1/1,000 to < 1/100): Anemia, dizziness, somnolence, vertigo, change in taste, constipation, pruritus, increased sweating, fatigue, malaise, and fever.

Serious Safety Considerations

Regulatory documents highlight rare but clinically important safety concerns that fall under the Hepatobiliary, Cardiac, and Skin systems:

  • Serious Hepatic Toxicity: This includes rare reports of hepatic failure or hepatocellular necrosis.
  • Cardiac Arrhythmias: Rare instances of QT interval prolongation and Torsade de Pointes have been documented.
  • Severe Cutaneous Reactions: Potentially life-threatening conditions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis are listed as rare adverse reactions.

Population-Specific Safety Notes

The label includes specific safety statements for certain groups. For example, the risk of a rare pattern of congenital anomalies is associated with chronic, high-dose use of Fluconazole during the first trimester of pregnancy. Additionally, specific caution is required for patients with renal impairment, as the drug’s elimination is affected by reduced kidney function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Fungustatin (Fluconazole) overdose requires immediate action based on documented risks. Overdose presentations include central nervous system (CNS) effects, such as hallucination and paranoid behavior. Of serious concern is the potential for life-threatening ventricular arrhythmias, including Torsade de pointes, which represents a severe, documented risk in high-exposure states.


Regulatory-Mandated Emergency Actions

If overdose is suspected, emergency services must be contacted immediately, particularly if the person has collapsed, has trouble breathing, or is unresponsive. Regulatory authorities mandate that upon exposure, symptomatic treatment and supportive measures be instituted.

Officially Documented Management

Management procedures are guided by the fact that no specific antidote is known. Treatment is focused on elimination, with supportive measures documented in regulatory information including gastric lavage when clinically appropriate. Hemodialysis is documented as an effective procedural measure, as it substantially reduces drug plasma concentrations. Clearance is also directly dependent on renal excretion, which is a critical factor in managing the drug’s elimination during an overdose situation.

Therapeutic Uses of Fungustatin

What Fungustatin Treats: Main Uses and Benefits

Fungustatin (Fluconazole) is generally relevant for easing symptoms that arise from systemic and localized fungal (yeast) infections. It is applied across therapeutic domains where additional symptomatic support is needed to address acute or recurrent manifestations.

The medication is commonly used to help manage various infection categories, including systemic infections (like Candidemia), mucosal infections (such as oral, esophageal, and vaginal candidiasis), and Cryptococcal Meningitis.

Fungustatin plays a role in managing symptoms related to systemic imbalance in critically ill patients and supports general well-being during symptomatic phases of deep-seated infection. For mucosal issues, the use is relevant for easing symptoms related to inflammatory or irritative states. It is also considered relevant for managing recurrent or episodic manifestations, providing a benefit that contributes to easing the overall symptom load for patients in high-risk groups.


Quick Fact: Relevant for Localized Irritation

Fungustatin is commonly used to help with conditions characterized by periods of heightened symptoms related to fungal growth, helping to ease the discomfort and inflammation of oral and genital thrush.

Eligibility and Restrictions for Use

Fungustatin (Fluconazole) eligibility is determined by official regulatory documents based on patient health status and age. The medicine is contraindicated for patients with a known hypersensitivity to Fluconazole or other azole antifungals.

Contraindications and Restrictions

Classification Population/Condition Constraint Basis
Absolute Contraindication Co-administration with specific drugs that prolong the QT interval and are metabolized via CYP3A4 (e.g., Cisapride, Terfenadine). Cardiac Risk/Interaction
Contraindication Hypersensitivity to Fluconazole or other azoles. Allergic History
Conditional Use Renal or Hepatic Impairment Organ Function
Restricted Use Pregnancy, particularly prolonged high-dose use. Physiological State

Eligibility requires caution in patients with pre-existing proarrhythmic cardiac conditions, such as advanced heart failure or prolonged QTc intervals. Use is conditional on assessing liver and kidney function, as regulatory information states the drug should be administered with caution to patients with hepatic dysfunction, and dosage adjustments are necessary for renal impairment.

Age-Specific Eligibility

The medicine is approved for adults and older adults, with no specific dose adjustment required for the elderly unless kidney function is reduced. Safety and effectiveness are established for specific indications in pediatric patients from the age of 6 months and older. Use in infants younger than 6 months requires careful determination by the prescriber, and use is not established for certain indications like genital candidiasis in children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory documentation for Fungustatin establishes clear restrictions regarding its use with other medicines, driven by its documented pharmacokinetic profile.

Formal Contraindications (Strict Prohibitions)

Co-administration with certain medicinal products is formally prohibited due to the risk of serious cardiac events, including Torsade de Pointes. The official list of forbidden substances includes Pimozide, Astemizole, Quinidine, and Cisapride.


Metabolic and Exposure Alterations

Fungustatin is a potent inhibitor of the metabolic enzymes CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This enzyme inhibition reduces the clearance of several co-administered medicines, resulting in increased systemic exposure. Substances whose plasma concentrations are increased include Warfarin (elevating bleeding risk), immunosuppressants like Cyclosporine and Tacrolimus, and certain Statins. Conversely, the antibiotic Rifampin is documented to enhance Fungustatin's metabolism, causing a reduction in its own plasma concentration.


Administration and Population Notes

The drug’s absorption is not affected by food and may be administered without regard to meals. A population-specific consideration notes that the diuretic Hydrochlorothiazide increases Fungustatin plasma levels due to reduced renal clearance, a finding particularly documented in official regulatory information concerning elderly patients.

Mechanism of Action

Targeted Inhibition of Fungal CYP51 Enzyme

Fungustatin acts as a non-competitive inhibitor of Lanosterol 14-alpha demethylase ( CYP51), a key enzyme in fungal cell function. The drug binds to the enzyme's heme iron, which prevents the catalytic function required for the ergosterol biosynthesis pathway.


Disruption of Cell Membrane Integrity and Viability

The enzyme blockade leads to the depletion of ergosterol, the key stabilizing sterol for the fungal cell membrane, while toxic methylated precursors accumulate. This structural failure compromises the membrane's integrity, leading to leakage and the fungistatic consequence of inhibiting cell division and expansion.


Constraints Imposed by Fungal Resistance Mechanisms

The drug's mechanism can be functionally limited when the fungal cell develops resistance, such as through gene mutations in ERG11 that prevent effective binding, or by overexpressing efflux pumps ( Cdr1, Mdr1) that actively expel Fungustatin before it can reach the target enzyme.

Dosage and Administration Information

Fungustatin (Fluconazole) is administered systemically through two main official routes: oral intake (via capsules, tablets, or reconstituted suspension) or intravenous (IV) infusion. Pharmacokinetic data confirms the drug's absorption is similar across both routes, with oral bioavailability noted as exceeding 90% compared to intravenous administration. This equivalence provides flexibility in choosing the administration method.

The standard protocol initiates therapy with a loading dose on the first day, which is twice the subsequent maintenance dose, a procedure designed to quickly achieve stable plasma concentrations. Following this initiation, the typical dosing frequency for prolonged regimens is once daily. The dose itself varies from 50 mg to 400 mg, based on the specific condition being addressed, although a single oral dose of 150 mg is established for some acute indications. Oral forms may be taken with or without food.

Procedural conditions must be followed for administration. When administered intravenously, the solution must be infused at a controlled rate, not exceeding 10 mL/minute. Furthermore, specific adjustments to the standard regimen are required based on the patient’s physiology: in adults with impaired kidney function (creatinine clearance le 50 mL/min), the daily maintenance dose is typically reduced by 50%. Pediatric administration is calculated on a weight-based (mg/kg) system, with modified frequency for certain neonatal age groups. The total duration of use is highly variable, ranging from a single-day treatment to long-term maintenance cycles lasting many months.

Recent Clinical Evidence

Research evidence / Overview of studies for Fungustatin

Evidence for Use in Systemic and Mucosal Candidiasis

Research for Fungustatin in treating candidiasis, which includes infections of the blood (systemic) and infections of moist areas like the mouth or esophagus (mucosal), includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to compare Fungustatin against other standard treatments or a control group. The core focus of this research was to measure outcomes related to physical discomfort and the presence of fungal organisms. Researchers monitored two main objectives: the Mycological Cure (the measured absence of the fungus in laboratory tests) and Clinical Cure/Response (the measured end of visible signs and reported symptoms).

Studies explored a wide range of patients, such as adults, critically ill patients, immunocompromised individuals, pediatric groups (including neonates), and women with vulvovaginal candidiasis. Findings describe patterns observed in the studies related to the short-term clearing of the fungal organism and the assessment of infection signs across various sites. What remains uncertain is the long-term status of some patients after treatment is complete, and research has highlighted the potential for reduced susceptibility or resistance to develop, particularly in certain non-albicans Candida species.


Evidence for Use in Cryptococcal Meningitis (Maintenance and Consolidation)

Research for Fungustatin in treating Cryptococcal Meningitis includes studies of the phases that follow initial treatment—known as consolidation and maintenance. Studies utilized randomized trial designs, often investigating Fungustatin as part of combination regimens, predominantly in adults and adolescents with HIV-associated disease.

Research monitored two critical outcomes: Mycological Clearance (tracking the status of the fungal organism in the Cerebrospinal Fluid or CSF) and the frequency of relapse during the long-term follow-up period. Research describing Fungustatin as a single agent for the initial phase of this disease is limited, as trials often evaluated combination therapy. Furthermore, the potential for drug resistance to develop in the Cryptococcus organism over the course of the extended maintenance phase is a factor noted in the scientific literature.


Evidence for Use in Prophylaxis (Preventive Care)

Fungustatin was studied for prophylaxis, or preventive care, in specific patient groups identified as high risk of developing a fungal infection. The evidence base includes robust Randomized Controlled Trials (RCTs) and subsequent large-scale Meta-analyses. Studies explored short-term changes in populations such as recipients of Hematopoietic Stem Cell Transplants (HSCT), chemotherapy patients with low white blood cell counts, and very low birth weight (VLBW) neonates. The research examined the incidence of invasive fungal infection (how often these infections occurred) and, in some cases, tracked outcomes related to patient survival during the high-risk period. While the evidence contributes to the broader evidence landscape, scientific reviews question whether widespread preventive use may contribute to the selection of fluconazole-resistant fungal strains over extended periods of time.

Frequently Asked Questions (FAQ)

Common questions about Fungustatin (FAQ)


Q: How quickly does Fungustatin usually start working?

Clinical studies describing the drug’s effects show that for the indication of vaginal candidiasis, the median time until the onset of symptom relief is described as one day. For more severe or deep-seated infections, the timeframe for feeling relief may take longer. This information is based on data reviewed in official product labeling.


Q: Are there any general expectations for how I will feel during the treatment course?

Based on clinical data, patients typically begin to experience symptom relief within the first few days of starting treatment with Fungustatin. However, the exact time it takes to feel the full effect depends on the specific type of infection being addressed and its overall severity. The importance of completing the full course as prescribed is documented in patient instructions.


Q: What should I do if I miss a dose of Fungustatin?

General patient instructions describe taking the dose as soon as it is remembered. If it is almost time for your next scheduled dose, regulatory patient information states that the missed dose is to be skipped. It is stated that a double dose should be avoided.


Q: What happens if I stop taking Fungustatin before the full course is finished?

Patient instructions describe the importance of completing the full prescribed duration of treatment, which is critical even if symptoms have improved. Stopping treatment early may allow the fungal infection to return and potentially make it harder to treat in the future. This practice is described as supporting the expected clinical outcome and helping to prevent the infection from returning.


Q: Is it safe to drink alcohol while taking Fungustatin?

While official documents do not describe a specific drug-alcohol interaction that affects how Fungustatin works, caution is generally advised. This is primarily due to the potential for additive side effects like headache or dizziness and to minimize increased stress on the liver, which the medication can already affect.


Q: Does Fungustatin affect birth control pills?

Studies reviewed in regulatory documentation indicate that Fungustatin may affect the plasma levels of certain hormones (such as ethinyl estradiol and norethindrone) found in some oral contraceptive pills. This effect is why an interaction is listed in the official product information.


Q: Can Fungustatin be crushed or split if swallowing is difficult?

Official patient information for the tablets indicates that they are typically designed to be swallowed whole. Therefore, the tablets are not generally to be cut, broken, or crushed unless a healthcare professional provides specific instructions to do so.


Q: Can Fungustatin be taken while breastfeeding?

Information supported by regulatory data indicates that the use of Fungustatin during breastfeeding is supported by regulatory data, which indicates that the amount excreted into breast milk is estimated to be below the dosage that would typically be given directly to an infant.


Q: What kind of infections is Fungustatin not effective against?

The drug's efficacy profile, as detailed in official microbiology data, lists specific limitations regarding certain organisms. For instance, the fungus Candida krusei should be considered resistant to Fungustatin, meaning the medicine is not considered an effective treatment for infections caused by this specific organism.


Q: Is there a generic version of Fungustatin available?

Yes, the active ingredient in Fungustatin is Fluconazole. As the patent status of the brand-name drug changes, generic versions containing Fluconazole become available on the market. These generic equivalents contain the same active ingredient and meet the same regulatory standards as the original medicine.


Q: What does 'contraindication' mean regarding Fungustatin?

The term contraindication, as used in official drug labeling, refers to a pre-existing medical condition or circumstance that makes the use of Fungustatin improper or potentially risky for the patient. For Fungustatin, this includes known hypersensitivity to the drug and co-administration with specific medications that can increase cardiac risk.


Q: Why is Fungustatin sometimes used for skin conditions?

Official indications for Fungustatin include treating fungal infections that affect various body sites, including moist skin areas. This includes certain types of candidiasis such as vaginal thrush and balanitis. The systemic action of the drug allows it to effectively address infections present in these areas.


Q: What are the signs of a serious allergic reaction to Fungustatin?

A serious allergic reaction is rare but is documented as requiring immediate clinical evaluation. Signs can include severe cutaneous reactions like Stevens-Johnson syndrome or symptoms such as breathing problems, swelling of the face or throat, widespread hives, and sudden dizziness or fainting. Information on these rare but serious events is detailed in the safety section of the official label.


Q: Does Fungustatin interfere with blood pressure medication?

Official regulatory documents list interactions with specific medications. Notably, the diuretic Hydrochlorothiazide is documented to increase the levels of Fungustatin in the bloodstream due to reduced elimination by the kidneys. This means caution is described in the official warnings when these two medicines are used together.


Q: Are there any specific lab tests needed before starting Fungustatin?

Regulatory documents describe caution in patients with renal or hepatic impairment and the potential need for monitoring these functions. Since Fungustatin’s elimination is affected by kidney health and rare hepatic toxicity is a serious safety consideration, these factors are typically assessed.


Q: What is the difference between Fungustatin and other similar antifungal medicines?

Fungustatin is a synthetic medication classified as a triazole antifungal agent. Its mechanism is described as selectively inhibiting a specific enzyme, which is essential for the fungal cell's ability to create a healthy cell membrane. This specific action defines its place within the broader antifungal medicine class.


Q: What is the shelf life of Fungustatin after the bottle is opened?

Storage requirements differ based on the product form. Official documents state that the liquid suspension must be discarded 14 days after it is prepared. Tablets and capsules should be stored in their original container, protected from excess heat and moisture, and generally remain stable until the expiration date printed on the packaging.


Q: Are there different forms of Fungustatin (e.g., tablet, liquid, cream)?

The official product information specifies that Fungustatin is available for systemic use as capsules, tablets, an oral suspension, and an intravenous solution. These different forms allow for various administration routes depending on the patient's needs. The medicine is not officially described in its primary product labeling as a cream for topical application.

How should Fungustatin be stored and disposed of?

How to Store and Dispose of Fungustatin (Fluconazole)

Official regulatory documents define specific storage and disposal requirements for Fungustatin, which vary by product form.

Storage Requirements

Product Form Temperature Constraint Special Handling
Capsules/Tablets Store below 30 C (86 F) Protect from excess heat and moisture.
Liquid Suspension 5 C to 30 C (41 F to 86 F) Do not freeze. Discard unused portion after 14 days.
All Forms Keep the container tightly closed and in its original packaging. Keep out of the reach of children.

Disposal Instructions

Expired or unused medication should not be flushed down a toilet. The preferred method for disposal is using an official medicine take-back program. For the intravenous solution, specific sharps disposal guidelines must be followed for used needles and syringes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fungustatin found in:

A-Z Index: